CorPath GRX STEMI Study

NCT04459299 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2023-12-20

No results posted yet for this study

Summary

This study will evaluate the performance of the CorPath GRX System in Robotic Primary PCI (RPPCI) in the treatment of ST-elevated myocardial infarction (STEMI).

Conditions

  • STEMI - ST Elevation Myocardial Infarction
  • CAD

Interventions

DEVICE

Robotic-PCI (CorPath GRX System)

Robotic-PCI for acute ST elevation myocardial infarction (STEMI).

Sponsors & Collaborators

  • Corindus Inc.

    lead INDUSTRY

Principal Investigators

  • Salvatore F Mannino, DO, MA · WellStar Health System

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-28
Primary Completion
2020-11-26
Completion
2020-11-29
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04459299 on ClinicalTrials.gov